144 related articles for article (PubMed ID: 38254797)
1. Histopathological Spectrum and Molecular Characterization of Liver Tumors in the Setting of Fontan-Associated Liver Disease.
Francalanci P; Giovannoni I; Tancredi C; Gagliardi MG; Palmieri R; Brancaccio G; Spada M; Maggiore G; Pietrobattista A; Monti L; Castellano A; Giustiniani MC; Onetti Muda A; Alaggio R
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254797
[TBL] [Abstract][Full Text] [Related]
2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease.
Sagawa T; Kogiso T; Sugiyama H; Hashimoto E; Yamamoto M; Tokushige K
Hepatol Res; 2020 Jul; 50(7):853-862. PubMed ID: 32219953
[TBL] [Abstract][Full Text] [Related]
5. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort.
Téllez L; Rodríguez de Santiago E; Minguez B; Payance A; Clemente A; Baiges A; Morales-Arraez D; La Mura V; Llop E; Garrido E; Garrido-Lestache E; Tasayco S; Bruno O; Prieto R; Montserrat S; Pons M; Olavarría A; Dos L; Legendre A; Jesús Del Cerro M; Bañares R; García-Pagán JC; Rautou PE; Albillos A;
J Hepatol; 2020 Apr; 72(4):702-710. PubMed ID: 31726116
[TBL] [Abstract][Full Text] [Related]
8. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
10. Fontan-associated liver disease: A review.
Gordon-Walker TT; Bove K; Veldtman G
J Cardiol; 2019 Sep; 74(3):223-232. PubMed ID: 30928109
[TBL] [Abstract][Full Text] [Related]
11. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Accurate Diagnosis of HCC in FALD: A Case Series.
Feeley M; Hopkins K; Grinspan LT; Schiano T; Love B; Chan A; Lewis S; Zaidi AN
Pediatr Cardiol; 2023 Oct; 44(7):1447-1453. PubMed ID: 37318608
[TBL] [Abstract][Full Text] [Related]
15. Benign Hepatic Nodules Mimicking Hepatocellular Carcinoma in the Setting of Fontan-associated Liver Disease: A Case Report.
Çolaklar A; Lehnert SJ; Tirkes T
Euroasian J Hepatogastroenterol; 2020; 10(1):42-44. PubMed ID: 32742972
[TBL] [Abstract][Full Text] [Related]
16. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
17. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
Abdelhamed W; El-Kassas M
World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
[TBL] [Abstract][Full Text] [Related]
18. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
19. Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedure - A Nationwide Survey in Japan.
Kuwabara M; Niwa K; Toyoda T; Shirai T; Tateno S; Ohuchi H; Tanaka Y; Ichida F; Fujisawa T; Akagi T; Mori Y;
Circ J; 2018 Mar; 82(4):1155-1160. PubMed ID: 29445059
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for Fontan-associated hepatocellular carcinoma.
Kogiso T; Sagawa T; Taniai M; Shimada E; Inai K; Shinohara T; Tokushige K
PLoS One; 2022; 17(6):e0270230. PubMed ID: 35714161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
